Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.48 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 16/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.39 |
| ▸ | DRD1 | P21728 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4124146 | 1.00 | SLC6A2 (0.48) | SLC6A2SLC6A4SLC6A3KCNH2TDO2 | |
| SCHEMBL4143909 | 0.91 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4143919 | 0.91 | SLC6A2 (0.47) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4132811 | 0.88 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4132817 | 0.88 | SLC6A2 (0.57) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4144969 | 0.85 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4144965 | 0.85 | SLC6A2 (0.53) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4137297 | 0.84 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4137293 | 0.84 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3KCNH2 | |
| SCHEMBL4142167 | 0.84 | SLC6A2 (0.54) | SLC6A2SLC6A4SLC6A3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215857-A1 | Therapeutic Pyrrolidines | PFIZER PRODUCTS INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215857-A1 | Therapeutic Pyrrolidines | OPRL1, HTR5A, OPRD1 | SLC6A2 28/4885SLC6A4 18/4885SLC6A3 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.